Scientist

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.

The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner.

These distinctive capabilities enable AP3’s direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates.

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types.

The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer.

Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368.

The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment.

In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally-discovered preclinical stage pipeline programs.

These include ACR-2316, a potent, selective WEE1 / PKMYT1 inhibitor designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, and a cell cycle program with an undisclosed target.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

Position Overview :

The Scientist will be a key member of Acrivon Therapeutics’ Drug Discovery Team and will be supporting its in vitro pharmacology, mechanism-of-action studies, and biomarker identification efforts.

This position will be based in Watertown, MA.

Duties and Responsibilities :

• Independently design and perform mid to high-throughput plate-based cellular assays to profile compounds, understand their mechanism of action, and / or identify relevant biomarkers.
• Perform cell line engineering, assay development, and large cell line panel screens.
• Analyze, interpret, and summarize data for team meeting presentations and document experiments in electronic lab notebook.
• Manage CROs for outsourced work.
• Work collaboratively in a team-oriented, matrixed, cross-functional context.

Requirements and Qualifications :

BS in Biological Sciences or a related discipline with 6+ years industry experience; or MS with 4+ years industry experience;

or Ph.D. with 2+ years experience.

• Extensive mammalian cell culture experience is required.
• Demonstrated hands-on experience with mid to high-throughput plate-based assays including target engagement, cell viability, and cell death assays (e.

g., ADP-Glo, NanoBRET, AlphaLISA, CellTiter-Glo, CellTox-Green, real-time live cell imaging) is preferred.

• Experience in cell line engineering using CRISPR and / or lentiviral methods + experience generating drug-resistant lines is preferred.
• Familiarity with liquid handling and automation is desirable.
• Flow cytometry and / or high content imaging experience is a plus.
• CRO management experience is a plus.
• Strong work ethic and great attention to detail.

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics.

In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.